EE05307B1 - Laiaspektrilised 2-aminobensoksasoolsulfoonamiidid kui HIV proteaasi inhibiitorid, nende kasutamine, farmatseutiline kompositsioon ja meetod retroviiruse replikatsiooni inhibeerimiseks - Google Patents

Laiaspektrilised 2-aminobensoksasoolsulfoonamiidid kui HIV proteaasi inhibiitorid, nende kasutamine, farmatseutiline kompositsioon ja meetod retroviiruse replikatsiooni inhibeerimiseks

Info

Publication number
EE05307B1
EE05307B1 EEP200300547A EEP200300547A EE05307B1 EE 05307 B1 EE05307 B1 EE 05307B1 EE P200300547 A EEP200300547 A EE P200300547A EE P200300547 A EEP200300547 A EE P200300547A EE 05307 B1 EE05307 B1 EE 05307B1
Authority
EE
Estonia
Prior art keywords
broad
spectrum
pharmaceutical composition
protease inhibitors
hiv protease
Prior art date
Application number
EEP200300547A
Other languages
English (en)
Estonian (et)
Inventor
Louis Nestor Ghislain Surleraux Dominique
Marie Helene Vendeville Sandrine
Gaston Verschueren Wim
T.M.M.G De Bethune Marie-Pierre
Augustinus De Kock Herman
Tahri Abdellah
Original Assignee
Tibotec Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharmaceuticals Ltd. filed Critical Tibotec Pharmaceuticals Ltd.
Publication of EE200300547A publication Critical patent/EE200300547A/xx
Publication of EE05307B1 publication Critical patent/EE05307B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200300547A 2001-05-11 2002-05-10 Laiaspektrilised 2-aminobensoksasoolsulfoonamiidid kui HIV proteaasi inhibiitorid, nende kasutamine, farmatseutiline kompositsioon ja meetod retroviiruse replikatsiooni inhibeerimiseks EE05307B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01201732 2001-05-11
PCT/EP2002/005212 WO2002092595A1 (en) 2001-05-11 2002-05-10 Broadspectrum 2-amino-benzoxazole sulfonamide hiv protease inhibitors

Publications (2)

Publication Number Publication Date
EE200300547A EE200300547A (et) 2004-02-16
EE05307B1 true EE05307B1 (et) 2010-06-15

Family

ID=8180286

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300547A EE05307B1 (et) 2001-05-11 2002-05-10 Laiaspektrilised 2-aminobensoksasoolsulfoonamiidid kui HIV proteaasi inhibiitorid, nende kasutamine, farmatseutiline kompositsioon ja meetod retroviiruse replikatsiooni inhibeerimiseks

Country Status (31)

Country Link
US (2) US7622490B2 (de)
EP (1) EP1387842B1 (de)
JP (1) JP4467889B2 (de)
KR (1) KR100878853B1 (de)
CN (1) CN100549007C (de)
AP (1) AP1652A (de)
AR (1) AR035970A1 (de)
AT (1) ATE429431T1 (de)
AU (1) AU2002310818B2 (de)
BG (1) BG66350B1 (de)
BR (1) BR0209594A (de)
CA (1) CA2444895C (de)
CY (1) CY1109247T1 (de)
CZ (1) CZ304524B6 (de)
DE (1) DE60232067D1 (de)
DK (1) DK1387842T3 (de)
EA (1) EA009590B1 (de)
EE (1) EE05307B1 (de)
ES (1) ES2325809T3 (de)
HR (1) HRP20031026B1 (de)
HU (1) HUP0400438A3 (de)
IL (1) IL158093A0 (de)
MX (1) MXPA03010258A (de)
NO (1) NO326883B1 (de)
NZ (1) NZ529250A (de)
OA (1) OA13134A (de)
PL (1) PL209029B1 (de)
PT (1) PT1387842E (de)
SK (1) SK287952B6 (de)
WO (1) WO2002092595A1 (de)
ZA (1) ZA200307799B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
WO2001034119A2 (en) 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20040009890A1 (en) 2002-01-07 2004-01-15 Erickson John W. Broad spectrum inhibitors
US7157489B2 (en) 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
PL1670773T3 (pl) * 2003-09-30 2007-06-29 Tibotec Pharm Ltd Sposób wytwarzania sulfonamidów benzoksazolu i ich związków pośrednich
US8193227B2 (en) 2003-12-11 2012-06-05 Abbott Laboratories HIV protease inhibiting compounds
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
DE602004021640D1 (de) 2003-12-23 2009-07-30 Tibotec Pharm Ltd Verfahren zur herstellung von (1s,2r)-3-ää(4-aminophenyl)sulfonylü(isobutyl)aminoü-1-benzyl-2-hydroxypropylcarbamidsäure-(3r,3as,6ar)-hexahydrofuroä2,3-büfuran-3-ylester
RS51073B (sr) 2003-12-23 2010-10-31 Tibotec Pharmaceuticals Ltd. Proces za pripremanje (3r,3as,6ar)-heksahidrofuro│2,3-b│ furan-3-il (1s,2r)-3-││(4-aminofenil) sulfonil│(izobutil) amino │-1-benzil-2-hidroksipropilkarbamata
MXPA06012909A (es) * 2004-05-07 2007-09-06 Sequoia Pharmaceuticals Inc Inhibidores de proteasa retroviral repelente de resistencia.
AU2006217922B2 (en) 2005-02-25 2012-04-05 Janssen Sciences Ireland Uc Protease inhibitor precursor synthesis
AR053845A1 (es) * 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
US20120220520A1 (en) * 2006-10-17 2012-08-30 Van T Klooster Gerben Albert Eleutherius Bioavailable combinations for hcv treatment
WO2014194519A1 (en) 2013-06-07 2014-12-11 Merck Sharp & Dohme Corp. Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8204879D0 (sv) 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
EP0445926B1 (de) 1990-03-09 1996-08-21 Milliken Research Corporation Organische Materialien, die sulfonamidogebundene Poly(oxyalkylen)gruppen tragen und ihre Herstellung
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ATE154800T1 (de) * 1992-08-25 1997-07-15 Searle & Co N-(alkanoylamino-2-hydroxypropyl)-sulfonamide verwendbar als retrovirale proteaseninhibitoren
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
AU7669794A (en) * 1993-08-24 1995-03-21 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
SK283569B6 (sk) 1993-10-01 2003-09-11 Astra Aktiebolag Spôsob spracovania jemne deleného práškového liečiva, zariadenie na vykonávanie tohto spôsobu a aglomeráty vyrobené týmto spôsobom
WO1996022287A1 (en) 1995-01-20 1996-07-25 G.D. Searle & Co. Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
US5756533A (en) * 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
AU717598B2 (en) 1995-03-10 2000-03-30 G.D. Searle & Co. Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6150556A (en) * 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US5705500A (en) * 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
JP2000515488A (ja) * 1995-11-15 2000-11-21 ジー．ディー．サール アンド カンパニー 置換スルホニルアルカノイルアミノヒドロキシエチルアミノスルホンアミド レトロウイルスプロテアーゼ阻害剤
DK0904060T3 (da) 1996-05-20 2004-04-13 Janssen Pharmaceutica Nv Antifungale præparater med forbedret biotilgængelighed
WO1998042318A1 (en) 1997-03-26 1998-10-01 Janssen Pharmaceutica N.V. Pellets having a core coated with an antifungal and a polymer
GB9717849D0 (en) 1997-08-23 1997-10-29 Seal Sands Chemicals Limited Preparation of pyridene derivatives
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
BR9814484A (pt) 1997-12-24 2000-10-10 Vertex Pharma "pró-drogas de inibidores de aspartil protease"
WO1999033795A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
WO1999033792A2 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
JP4776775B2 (ja) 1998-06-23 2011-09-21 アメリカ合衆国 Ｈｉｖ感染哺乳動物を治療するための医薬組成物
WO1999067254A2 (en) * 1998-06-23 1999-12-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Multi-drug resistant retroviral protease inhibitors and use thereof
OA12464A (en) * 2001-04-09 2006-05-24 Tibotec Pharm Ltd Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide HIV protease inhibitors.

Also Published As

Publication number Publication date
HUP0400438A2 (hu) 2004-08-30
AR035970A1 (es) 2004-07-28
EA200301234A1 (ru) 2004-04-29
US7622490B2 (en) 2009-11-24
ES2325809T3 (es) 2009-09-18
PL209029B1 (pl) 2011-07-29
JP2004534757A (ja) 2004-11-18
DK1387842T3 (da) 2009-08-10
EP1387842A1 (de) 2004-02-11
HUP0400438A3 (en) 2007-08-28
HRP20031026A2 (en) 2005-10-31
SK14902003A3 (sk) 2004-07-07
WO2002092595A1 (en) 2002-11-21
CY1109247T1 (el) 2014-07-02
BG66350B1 (bg) 2013-08-30
CN1507446A (zh) 2004-06-23
AP1652A (en) 2006-08-11
JP4467889B2 (ja) 2010-05-26
ATE429431T1 (de) 2009-05-15
AP2003002904A0 (en) 2003-12-31
MXPA03010258A (es) 2005-03-07
HRP20031026B1 (hr) 2012-07-31
EP1387842B1 (de) 2009-04-22
US20040106661A1 (en) 2004-06-03
BR0209594A (pt) 2004-03-30
DE60232067D1 (de) 2009-06-04
CA2444895C (en) 2011-02-15
NO326883B1 (no) 2009-03-09
ZA200307799B (en) 2005-03-30
CZ304524B6 (cs) 2014-06-18
CZ20033290A3 (cs) 2004-05-12
NO20034988D0 (no) 2003-11-10
IL158093A0 (en) 2004-03-28
KR20040022417A (ko) 2004-03-12
OA13134A (en) 2006-12-13
BG108309A (bg) 2004-12-30
SK287952B6 (sk) 2012-06-04
NZ529250A (en) 2005-05-27
CN100549007C (zh) 2009-10-14
AU2002310818B2 (en) 2007-12-13
PT1387842E (pt) 2009-07-20
EE200300547A (et) 2004-02-16
CA2444895A1 (en) 2002-11-21
HK1062912A1 (en) 2004-12-03
EA009590B1 (ru) 2008-02-28
KR100878853B1 (ko) 2009-01-15
US7863306B2 (en) 2011-01-04
US20100029632A1 (en) 2010-02-04
PL366780A1 (en) 2005-02-07

Similar Documents

Publication Publication Date Title
EE200300381A (et) Laiaspektrilised 2-(asendatud amino)bensotiasoolsulfoonamiidid kui HIV proteaasi inhibiitorid, nende valmistamismeetod ja kasutamine, farmatseutilinekompositsioon ja meetod retroviiruse replikatsiooni inhibeerimiseks
EE200300547A (et) Laiaspektrilised 2-aminobensoksasoolsulfoonamiidid kui HIV proteaasi inhibiitorid, nende kasutamine, farmatseutiline kompositsioon ja meetod retroviiruse replikatsiooni inhibeerimiseks
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
DK1320531T3 (da) Bicyclo-pyrazoler, der er aktive som kinase inhibitorer, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger, der indeholder disse
BR0112292A (pt) Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto
DK1564210T3 (da) 4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
NO20031672D0 (no) Aza- og polyaza-naftalenylkarboksamider for anvendelse som HIV-integraseinhibitorer
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
HUP0303363A2 (hu) Kináz-inhibitor hatású heterociklusos vegyületek alkalmazása gyógyszerkészítmények előállítására
DK1399444T3 (da) Nye heterocycliske forbindelser, fremgangsmåde til fremstilling af samme samt anvendelse deraf som lægemidler, især som antibakterielle midler
EE200300369A (et) Atsüülitud indanüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
HUP0400202A3 (en) Imidazolidindion derivatives having metalloproteinase inhibitor effect, their use and pharmaceutical compositions containing them
HUS1200031I1 (hu) Dipeptidil peptidáz IV ciklopropil-kondenzált pirrolidin-bázisú inhibitorai és eljárás elõállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0400175A2 (en) Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity, their use and pharmaceutical compositions containing them
IL159076A0 (en) Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
DK1268431T3 (da) 3-Cyanoquinoliner, 3-cyano-1,6-naphthyridiner og 3-cyano-1,7-naphthyridiner som proteinkinaseinhibitorer
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
AU2002354801A1 (en) Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use
BRPI0507628A (pt) composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
HUP0400193A3 (en) Imidazolindion derivatives as metalloproteinase inhibitors, their use and pharmaceutical compositions containing them
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
DK1322158T3 (da) Farmaceutiske præparater med langvarig frigivelse, som indeholder metformin, og fremgangsmåde til fremstilling deraf
NL1024676A1 (nl) HIV integrase-remmers, farmaceutische preparaten en methoden voor het gebruik daarvan.
NO20023643D0 (no) Forbindelser som har antitumoraktivitet, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger som inneholderdem

Legal Events

Date Code Title Description
HE1A Change of address
HE1A Change of address
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20160510